Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

1.52
-0.0300-1.94%
Post-market: 1.45-0.0700-4.61%17:03 EST
Volume:176.76K
Turnover:277.25K
Market Cap:17.36M
PE:-0.80
High:1.72
Open:1.60
Low:1.51
Close:1.55
52wk High:7.95
52wk Low:1.42
Shares:11.42M
Float Shares:9.35M
Volume Ratio:1.54
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9054
EPS(LYR):-2.2184
ROE:-335.45%
ROA:-49.76%
PB:6.86
PE(LYR):-0.69

Loading ...

Vivos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Gregg C. Johnson

Reuters
·
11 hours ago

Vivos Therapeutics Appoints Gregg Johnson to Board

TIPRANKS
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares

Reuters
·
Feb 06

Vivos Therapeutics Partners with SoundHealth to Expand Access to Sleep and Allergy Technologies

Reuters
·
Feb 05

Vivos Therapeutics and Soundhealth Announce Collaboration to Expand Access to Soundhealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies

THOMSON REUTERS
·
Feb 05

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

GlobeNewswire
·
Jan 21

Vivos Therapeutics Completes Warrant Inducement Financing Transaction

TIPRANKS
·
Jan 21

Vivos Therapeutics Raises $4.6 Million Through Warrant Exercise at Reduced Price

Reuters
·
Jan 21

Vivos Therapeutics Secures Convertible Bridge Financing Facility

TIPRANKS
·
Jan 17

Vivos Therapeutics Secures $5.5 Million in Unregistered Private Placement

Reuters
·
Jan 17

Vivos Therapeutics Raises $4.64 Million Through Warrant Exercise

Reuters
·
Jan 16

Press Release: Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Dow Jones
·
Jan 16

Alliance Global Partners Sticks to Its Hold Rating for Vivos Therapeutics (VVOS)

TIPRANKS
·
Jan 09

Vivos Therapeutics Opens New Sleep Center in Auburn Hills, Michigan

Reuters
·
Dec 16, 2025

Vivos Therapeutics Executives Join Water Tower Research Online Fireside Chat

Reuters
·
Dec 16, 2025

Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital

Reuters
·
Dec 06, 2025

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 03, 2025

Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges

TIPRANKS
·
Nov 22, 2025

Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift

TIPRANKS
·
Nov 20, 2025

Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025

Reuters
·
Nov 20, 2025